Lotus Eye Hospital & Institute Ltd (LOTUSEYE) — shareholding pattern, promoter holding, financials and share price
About Lotus Eye Hospital & Institute Ltd (LOTUSEYE)
Lotus Eye Hospital & Institute Ltd operates in the Hospital industry, within the Healthcare sector. It trades on the NSE as LOTUSEYE and on the BSE under scrip code 532998. Its ISIN is INE947I01017.
Incorporated in 1990, Lotus Eye Hospital and Institute Ltd provides ophthalmology and other related services. [1]
Lotus Eye Hospital & Institute Ltd is a renowned eye care hospital group situated in South India, specializing in super-specialty services related to ophthalmology.
The company operates seven centers across major cities, offering advanced eye care through cutting-edge technologies like LASIK and Zyoptix, backed by expert ophthalmologists.
Listed peers in Hospital: Asarfi Hospital Ltd, Hannah Joseph Hospital Ltd, Aashka Hospitals Ltd, Abate As Industries Ltd, Fortis Malar Hospitals Ltd, Maitreya Medicare Ltd.
Valuation & Returns
10 Jul 2026At ₹118.25 a share on 10 Jul 2026, Lotus Eye Hospital & Institute Ltd (LOTUSEYE) was valued at a price-to-earnings ratio of 3,073.96x against an industry P/E of 61.73x and a price-to-book of 4.1x on a book value of ₹28.85 per share as of Mar 2025. Solomo computes return on equity of 0.13% and return on capital employed of 1.26% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 3,073.96x
- Industry P/E
- 61.73x
- P/B
- 4.1x
- EPS (TTM)
- ₹0.04
- Book value / share
- ₹28.85
- ROE
- 0.13%
- ROCE
- 1.26%
- ROA
- 0.11%
- Debt / equity
- 0.06x
- Dividend yield
- 0%
- EBITDA margin
- 8.47%
- 52-week range
- ₹71.1 – ₹153
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Lotus Eye Hospital & Institute Ltd (LOTUSEYE) reported revenue of ₹53.71 crore, net profit of ₹0.08 crore and earnings per share of ₹0.04. That compares with revenue of ₹49.55 crore and net profit of ₹0.74 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹13.61 crore and net profit ₹-0.32 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 38.9 | 47.03 | 48.2 | 49.55 | 53.71 |
| Net profit (₹ cr) | 2.98 | 4.08 | 2.91 | 0.74 | 0.08 |
| EPS (₹) | 1.43 | 1.96 | 1.4 | 0.36 | 0.04 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 5.30% | 4.09% | 8.40% | 2.80% |
| Profit growth | 24.78% | -7.03% | -37.20% | -74.57% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 40.14% of Lotus Eye Hospital & Institute Ltd (LOTUSEYE) (unchanged from the previous quarter) and domestic institutional investors (DII) hold 0.02%. Promoters have pledged 87.1% of their holding. Market capitalisation was ₹246 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2010.
Largest disclosed public shareholders in Jun 2026: Kovai Purani Finance Private Limited 7.93%, Vramath Investment Consultancy Private Limited 4.84%, Vramath Financial Services Private Limited 4.67%, Rajiv Choudhary 4.53%, Sangeeta Choudhary 3.92%, Thomas Santosh 2.66%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 40.14% | 87.1% | - | 0.02% | 59.86% |
| Mar 2026 | 40.14% | 87.1% | 0% | 0.02% | 59.86% |
| Dec 2025 | 39.67% | - | 0.01% | 2.46% | 60.33% |
| Sep 2025 | 40.64% | - | 0% | 0.02% | 59.36% |
| Jun 2025 | 40.39% | - | 0.01% | 0.02% | 59.61% |
| Mar 2025 | 40.22% | - | - | 0.04% | 59.78% |
| Dec 2024 | 40.14% | - | - | 0.04% | 59.86% |
| Sep 2024 | 40.03% | - | 0% | 0.03% | 59.97% |